Runlin Gao 



Chinese Society of Engineering, Beijing, China


Chinese Academy of Medical Sciences


Fuwai Cardiovascular Diseases Hospital

Professor Runlin Gao graduated from PUHSC in 1965 and won his Master’s Degree in PUMC in 1981; from 1985 to 1986, he studied interventional treatment for cardiovascular diseases in Loma Linda University Medical Center. He used to be Chairman of the Chinese Academy of Medical Sciences, Head of the Institute of Cardiovascular Diseases and President of Fuwai Cardiovascular Disease Hospital, Vice Chairman of CMDA and Chairman of Chinese Society of Cardiology. He now serves as Chief Expert of the Department of Cardiology, researcher and doctoral supervisor in the hospital and Chairman of the Expert Committee of National Center for Cardiovascular Diseases, as well as Editor-in-chief of National Medical Journal of China, Honorary Editor-in-chief of Chinese Journal of Cardiology, Editor-in-chief of Chinese Circulation Journal, Deputy Editor-in-chief of Chinese Edition of BMJ and editorial advisory board member of many domestic and overseas journals, including European Heart Journal. In 1999, he was selected among Middle-aged and Young Experts of Prominent Contributions and was elected to be academician of the Chinese Academy of Engineering that year. He also served as a member of the Ninth, Tenth and Eleventh CPPCC National Committee.

He’s a famous expert of cardiology and academic leader in China, as well as a pioneer in interventional treatment of coronary heart diseases who made significant contributions to China’s building and development of interventional cardiology. His research finding “Techniques of Interventional Treatment of Cardiovascular Diseases and Applied Research” won the second place in National Science and Technology Progress Award in 1997. Runlin Gao is also committed to the most important problem faced by interventional cardiology, namely, research of the mechanism of restenosis and prevention, seeking the feasibility of applying framework gene to prevent restenosis. The project of transgenic technology of protein-coated stent he hosted won patents in the US and China. “Experimental Research of the Mechanism and Prevention of Restenosis after Interventional Treatment of Cardiovascular Diseases” won the second place in Chinese Medical Science and Technology Award in 2001. He’s been striving for domestication of drug eluting stent by cooperating with domestic manufacturers to develop new-type drug stent and conducting animal experiment and clinical researches, thus driving homemade drug eluting stent into the market and applying it to clinical practices. His cooperative scientific achievement “A Key Technology of the Design and Manufacturing of Drug Eluting Stent for Coronary Artery” won the second place in National Science and Technology Progress Award in 2007. As for researches of clinical pharmacology and evidence-based medicine of cardiovascular diseases, Runlin Gao, as the chief researcher, took charge of Phase-II clinical test of recombinant SAK and recombinant neuregulin of homemade Type-I New Drug, making great efforts for preparation of new drugs in China. Also, as a national chief researcher, he initiated several int’l multicenter-clinical trials; as a principal investigator, he also conducted several nationwide registered researches, such as CCSR, registered research of left main coronary stent implantation, CPACS and registered research of stable coronary heart disease, thus accumulating a lot of data for China’s evidence-based medicine and spotting the gap between the clinical practices and clinical guidelines in China so as to make targeted efforts in narrowing the gap.

Long working on the frontline of clinical practices,Professor Runlin Gao has rich clinical experience and achieved outstandingly in the Cardiology, especially coronary heart disease, pathophysiology and treatment of angina, reperfusion therapy of acute myocardial infarction, clinical application of thrombolytic drug, bedsides hemodynamic monitoring, percutaneous IABP and rescue of severe cases of cardiovascular diseases. In 1999, he was granted “Special Contribution Award” by the Central Healthcare Committee; also in that year, he was elected to be Beijing Model Worker and Outstanding Worker in National Health Institutions.